A specific heterogeneous enzyme-linked immunosorbent assay (ELISA) has been established in order to determine levels of low-molecular-weight epidermal growth factor (EGF) in the urine of patients with renal cell carcinoma who had undergone unilateral radical nephrectomy. Urine specimens, i.e., 20 pr
An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases
β Scribed by Chow, N. H. ;Tzai, T. -S. ;Cheng, P. -E. ;Chang, C. -J. ;Lin, J. S. -N. ;Tang, M. -J.
- Publisher
- Springer
- Year
- 1994
- Tongue
- English
- Weight
- 837 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
To characterize epidermal growth factor-related transforming growth factors in the urine of patients with hepatocellular carcinoma, gel filtration with Bio-Gel P-30 was performed in seven hepatocellular carcinoma patients and seven sex-matched and agematched healthy controls. Distinct profiles of so
We report the cutaneous side-effects of ZD1839 (Iressa), a new anticancer agent that acts by inhibiting epidermal growth factor (EGF) receptor signal transduction. Three patients receiving ZD1839 developed an eruption consisting of follicular papules and pustules in an acneiform distribution as well
We reassessed the enzyme immunoassay (EIA) system for hEGF previously developed by our laboratory ( C h ChimActa 15651-60, 1985), since it appeared that the reported EIA system detected not only hEGF but also pS2 protein owing to minor contamination by pS2 protein in the hEGF sample used for immuniz